Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Ambra-1 and Loricrin as biomarkers for disease progression in melanoma

Ambra-1 and Loricrin as biomarkers for disease progression in melanoma

US Patent 10634678 · Granted Apr 28, 2020

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Monoclonal antibodies against loricrin2025
Monoclonal antibodies against loricrin2025
Monoclonal antibodies against Ambra-12025
Monoclonal antibodies against Ambra-12025
Skin model2019
Game dressing tool2016
Clinical data monitoring2014
Clinical guidelines engine2013
Methods and apparatus for responding to request for clinical information2013